223 related articles for article (PubMed ID: 24440278)
21. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.
Cigognetti M; Lonardi S; Fisogni S; Balzarini P; Pellegrini V; Tironi A; Bercich L; Bugatti M; Rossi G; Murer B; Barbareschi M; Giuliani S; Cavazza A; Marchetti G; Vermi W; Facchetti F
Mod Pathol; 2015 Aug; 28(8):1043-57. PubMed ID: 26022455
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions.
Önder S; Özogul E; Koksal D; Sarinc Ulasli S; Firat P; Emri S
Cytopathology; 2019 Nov; 30(6):592-600. PubMed ID: 31165505
[TBL] [Abstract][Full Text] [Related]
23. p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections.
Mayall FG; Goddard H; Gibbs AR
J Pathol; 1992 Dec; 168(4):377-81. PubMed ID: 1484319
[TBL] [Abstract][Full Text] [Related]
24. Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistry.
Kushitani K; Takeshima Y; Amatya VJ; Furonaka O; Sakatani A; Inai K
Pathol Int; 2008 Feb; 58(2):75-83. PubMed ID: 18199156
[TBL] [Abstract][Full Text] [Related]
25. D2-40: a reliable marker in the diagnosis of pleural mesothelioma.
Müller AM; Franke FE; Müller KM
Pathobiology; 2006; 73(1):50-4. PubMed ID: 16785767
[TBL] [Abstract][Full Text] [Related]
26. IMP3 and GLUT-1 immunohistochemistry for distinguishing benign from malignant mesothelial proliferations.
Lee AF; Gown AM; Churg A
Am J Surg Pathol; 2013 Mar; 37(3):421-6. PubMed ID: 23108021
[TBL] [Abstract][Full Text] [Related]
27. Assessment of cell cycle state may facilitate the histopathological diagnosis of malignant mesothelioma.
Sington JD; Morris LS; Nicholson AG; Coleman N
Histopathology; 2003 May; 42(5):498-502. PubMed ID: 12713628
[TBL] [Abstract][Full Text] [Related]
28. A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.
Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Sato A; Tsujimura T; Ueda H; Makihata S; Kato F; Iwasaki A; Nabeshima K
Lung Cancer; 2018 Nov; 125():198-204. PubMed ID: 30429020
[TBL] [Abstract][Full Text] [Related]
29. Value of claudin-4 immunostaining in the diagnosis of mesothelioma.
Ordóñez NG
Am J Clin Pathol; 2013 May; 139(5):611-9. PubMed ID: 23596113
[TBL] [Abstract][Full Text] [Related]
30. The "Brescia panel" (Claudin-4 and BRCA-associated protein 1) in the differential diagnosis of mesotheliomas with epithelioid features versus metastatic carcinomas.
Bernardi L; Bizzarro T; Pironi F; Szymczuk S; Buda R; Fabbri E; Di Claudio G; Rossi G
Cancer Cytopathol; 2021 Apr; 129(4):275-282. PubMed ID: 33045147
[TBL] [Abstract][Full Text] [Related]
31. Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes.
Churg A; Nabeshima K; Ali G; Bruno R; Fernandez-Cuesta L; Galateau-Salle F
Lung Cancer; 2018 Oct; 124():95-101. PubMed ID: 30268487
[TBL] [Abstract][Full Text] [Related]
32. Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.
Berg KB; Dacic S; Miller C; Cheung S; Churg A
Arch Pathol Lab Med; 2018 Dec; 142(12):1549-1553. PubMed ID: 30059257
[TBL] [Abstract][Full Text] [Related]
33. c-MET immunohistochemistry for differentiating malignant mesothelioma from benign mesothelial proliferations.
Ren HZ; Cheung S; Churg A
Hum Pathol; 2020 Nov; 105():31-36. PubMed ID: 32916162
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis.
Wu D; Hiroshima K; Matsumoto S; Nabeshima K; Yusa T; Ozaki D; Fujino M; Yamakawa H; Nakatani Y; Tada Y; Shimada H; Tagawa M
Am J Clin Pathol; 2013 Jan; 139(1):39-46. PubMed ID: 23270897
[TBL] [Abstract][Full Text] [Related]
35. My approach to the diagnosis of mesothelial lesions.
Butnor KJ
J Clin Pathol; 2006 Jun; 59(6):564-74. PubMed ID: 16731600
[TBL] [Abstract][Full Text] [Related]
36. Cadherins, catenins and APC in pleural malignant mesothelioma.
Abutaily AS; Collins JE; Roche WR
J Pathol; 2003 Nov; 201(3):355-62. PubMed ID: 14595746
[TBL] [Abstract][Full Text] [Related]
37. Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies.
Cagle PT; Churg A
Arch Pathol Lab Med; 2005 Nov; 129(11):1421-7. PubMed ID: 16253023
[TBL] [Abstract][Full Text] [Related]
38. The differential diagnosis of epithelial-type mesothelioma from adenocarcinoma and reactive mesothelial proliferation.
Soosay GN; Griffiths M; Papadaki L; Happerfield L; Bobrow L
J Pathol; 1991 Apr; 163(4):299-305. PubMed ID: 2033489
[TBL] [Abstract][Full Text] [Related]
39. Value of mesothelin immunostaining in the diagnosis of mesothelioma.
Ordóñez NG
Mod Pathol; 2003 Mar; 16(3):192-7. PubMed ID: 12640097
[TBL] [Abstract][Full Text] [Related]
40. HEG1 Is a Highly Specific and Sensitive Marker of Epithelioid Malignant Mesothelioma.
Naso JR; Tsuji S; Churg A
Am J Surg Pathol; 2020 Aug; 44(8):1143-1148. PubMed ID: 32205484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]